-
Walvax Biotechnology’s Weuphoria Vaccine Approved in Oman for Pediatric Pneumococcal Infections
•
Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that it has received market approval in the Sultanate of Oman for its vaccine Weuphoria, a 13-valent pneumococcal polysaccharide conjugate vaccine (PCV-13). This approval marks a significant step for the company as it expands the reach of its…
-
Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition
•
Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE: 300142), has released its financial report for the first half of 2024. The company reported operating revenue of RMB 1.433 billion, marking a significant year-on-year (YOY) decrease of 33.88%. The non-net profit attributable to the…
-
Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China
•
Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human papillomavirus (HPV) vaccine to a record low of RMB 27.5 per dose for domestic products, according to the Shandong Center for Disease Control and Prevention’s disclosure of the 2024 purchase transaction data for the vaccine…
-
Walvax Biotechnology’s Bivalent HPV Vaccine Earns WHO Pre-Qualification Status
•
China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has achieved a significant milestone with its bivalent human papillomavirus vaccine, which has received pre-qualification (PQ) status from the World Health Organization (WHO). This vaccine, designed to prevent cervical cancer and other diseases associated with high-risk HPV types 16 and 18, was commercially…
-
Walvax Biotechnology Halts COVID-19 mRNA Vaccine Trials Co-Developed with Abogen Biosciences
•
Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the termination of clinical trials for a COVID-19 mRNA vaccine that was co-developed with Abogen Biosciences Co., Ltd, a specialized developer of messenger ribonucleic acid (mRNA) drugs. This decision also affects the technology development cooperation between…
-
Walvax Biotechnology Halts COVID-19 Vaccine Clinical Trials Citing Low Benefits
•
Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the termination of clinical studies for its recombinant COVID-19 vaccine (CHO cell) and recombinant COVID-19 variant vaccine (CHO cell), due to the assessment of low economic and social benefits. The vaccines were approved for clinical trials…
-
Walvax Biotechnology’s COVID-19 Variant Vaccine RQ3033 Shows Positive Phase III Results
•
China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has announced positive results from a Phase III immunogenic bridge study for its COVID-19 variant mRNA vaccine candidate, RQ3033, co-developed with Fudan University and RNACure. The vaccine is specifically targeting the Omicron XBB.1.5 variant and has demonstrated good efficacy and safety in the…
-
Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge
•
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs) for their COVID-19 vaccines targeting the Omicron XBB variant. Among the notable developments are Lizhu Pharmaceutical’s (HKG: 1513) recombinant bivalent vaccine, which combines the prototype strain with the Omicron XBB variant, and CanSino Biologics’ (SHA:…
-
Walvax Biotechnology Secures BPOM Approval for Weuphoria Pneumococcal Vaccine
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received market approval from the Indonesian Food and Drug Control Agency (BPOM) for its Weuphoria, a 13-valent pneumococcal polysaccharide conjugate vaccine (PCV-13). This approval is a significant milestone for Walvax as it expands its reach into the Indonesian…
-
Walvax Biotechnology Receives Indonesian FDA Approval for Phase III Pneumococcal Vaccine Trial
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received approval from the Food and Drug Supervisory Agency of Indonesia to initiate a Phase III clinical study for its Weuphoria, a 13-valent pneumococcal polysaccharide conjugate vaccine. Study Design and ObjectivesThe Phase III study is a randomized, blinded,…
-
Walvax Biotechnology’s RQ3013 mRNA Vaccine Shows Efficacy in Phase III Study
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the efficacy interim results of a Phase III clinical study for its RQ3013, a bivalent mRNA vaccine based on the S protein chimera of Alpha/Beta SARS-CoV-2 variants. The study provides crucial data on the vaccine’s performance as a sequential booster in…
-
Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy results of a Phase IIIb clinical study for its RQ3013, a bivalent mRNA vaccine based on the S protein chimera of Alpha/Beta SARS-CoV-2 variants. The vaccine was co-developed by Shanghai Llanque Biomedical Co., Ltd and…
-
AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open Phase I clinical study for its ACYW135 meningococcal polysaccharide conjugate vaccine, MCV4. The study is expected to enroll 120 subjects, marking a significant step in the development of this vaccine. Market Context and CompetitionCurrently, commercially…
-
Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with Indonesia-based PT Etana Biotechnologies (Etana) for PCV and HPV vaccines. This builds on an earlier agreement for Etana to provide local manufacturing of Walvax Bio’s COVID-19 mRNA vaccine in Indonesia. Financial details of the partnership…
-
Walvax Biotech Launches Phase IIIb Trial for mRNA COVID-19 Vaccine
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb clinical study with ethics approval. The study is designed to assess the immunogenicity and safety of its “novel coronavirus variant mRNA vaccine” (S protein chimera) in individuals aged 18 and above who have completed three…
-
Walvax Biotech Enrolls First Subject in Phase III HPV Vaccine Study
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced the first subject enrollment for a Phase III clinical study assessing the immunogenicity of its in-house developed nine-valent human papillomavirus (HPV) vaccine compared with Merck Sharp & Dohme’s (MSD) Gardasil 9. The vaccine is designed for the prevention of cervical cancer, vulvar…
-
Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has received clinical trial approvals from the National Medical Products Administration (NMPA) for two novel coronavirus vaccines: an mRNA vaccine co-developed with Fudan University and Shanghai RNACure Biopharma, and a recombinant vaccine developed in-house by its subsidiary Shanghai Zerun Biotech. Vaccine Details Strategic…
-
Walvax’s mRNA Vaccine AWcorna Shows Superior Immune Response in Phase III Trial
•
Walvax Biotechnology Co., Ltd’s (SHE: 300142) mRNA vaccine against SARS-CoV-2, named AWcorna, has reached the Phase III stage in multiple trial centers. The randomized trial (ChiCTR2100053701), led by the Academy of Military Medical Sciences and the Guangzhou Institute of Respiratory Health, enrolled 300 adults who had previously received two doses…
-
Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical study and end development for its recombinant enterovirus 71 (EV71) virus vaccine (Pichia pastoris). The company’s press release states that the recombinant EV71 vaccine, which first entered clinical trials in China in June 2019, was…
